|出版日期||內容資訊||英文 108 Pages
本報告以癌症免疫及各種癌症免疫級為主題，提供3位關鍵意見領袖的採訪、 BioMedTracker的開發平台資料，Pharma & MedTech Business Intelligence 及 Medtrack的契約資訊等。
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions.
Datamonitor Healthcare anticipates that the PD-1/PD-L1 class will gain approvals for multiple tumor types, and that this class will be the most commercially successful immuno-oncology class over the next 10 years. As monotherapies, PD-1 inhibitors will become the first-line treatment of choice in melanoma, and they are also likely to gain further approvals for a wide variety of cancers.
CAR-T cell therapy early clinical results are extremely promising. The leading CD19-targeted CAR-T treatments from Novartis, Juno, and Kite all provide response rates hovering around 90% for patients with multiply relapsed or refractory acute lymphoblastic leukemia.
Expectations for cancer vaccines have diminished after multiple failures. In theory, a cancer vaccine treatment should be able to strengthen the immune response against a cancer and help to prevent it from recurring. In practice, a series of Phase III studies investigating cancer vaccines have failed to meet their primary endpoints, and the potential future role of this class has diminished with each trial failure.
Three key opinion leaders were interviewed for this analysis, with the full interviews being transcribed. Pipeline data were provided by BioMedTracker, and deals information was provided by Pharma & MedTech Business Intelligence and Medtrack.